



1638
PATENT
IMC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mukerji et al.

Serial No.: 10/060,793 ✓

Filed: January 30, 2002

For: DESATURASE GENES, ENZYMES
ENCODED THEREBY AND USES
THEREOF

Case No.: 6884.US.01

Examiner: McElwain, E.F.

Group Art Unit: 1638

Certificate of Mailing under 37
CFR §1.8(a):

I hereby certify that this paper
(along with any paper referred to
as being attached or enclosed) is
being deposited with the United
States Postal Service with
sufficient postage as First Class
Mail addressed to as follows:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date of Deposit: 5/11/04

Kimberly A. Iorio
Kimberly A. Iorio

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith for the patent application identified above entitled
DESATURASE GENES, ENZYMES ENCODED THEREBY AND USES THEREOF are the
following:

1. Response to Notice to Comply and Supplemental Preliminary
Amendment (5 Pages);
2. Copy of Notice to Comply (1 Page);
3. Substitute Paper Copy of the Sequence Listing (26 Pages);
4. Substitute Computer Readable Form Copy (1 Diskette);
5. Statement to Support Filings and Submissions in Accordance
with 35 CFR §§1.821-1.825 (1 Page); and
6. Return Receipt Postcard.

- The Commissioner is hereby authorized to charge any additional Filing
Fees required under 37 CFR §1.16, as well as any patent application
processing fees under 37 CFR §1.17 associated with this communication
for which full payment had not been tendered, to Deposit Account No.
01-0025. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
Mukerji, et al.

ABBOTT LABORATORIES
Customer No.: 23492
Telephone: (847) 938-7576
Facsimile: (847) 938-2623

Cheryl L. Becker
Cheryl L. Becker
Registration No. 35,441
Attorney for Applicants

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to these regulations, published at 114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.



2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).



3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).



4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."



5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).



6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).



7. Other: See the attached page regarding sequences in the specification not included in the CRF

Applicant must provide:



An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"



An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification



A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.